Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
5
×
boston blog main
clinical trials
fda
biotech
boston top stories
boston
detroit blog main
detroit top stories
drugs
indiana blog main
indiana top stories
national top stories
raleigh-durham blog main
raleigh-durham top stories
roche
acute hepatic porphyrias
akin akinc
alnylam pharmaceuticals
alprazolam
amgen
aminolevulinic acid
bempedoic acid
biopharma
blueprint medicines
boulder/denver blog main
boulder/denver top stories
cancer
cgrp inhibitors
cholesterol
chronic migraine
colucid pharmaceuticals
companion diagnostic
corticosteroids
deals
detroit
dna sequencing
drug enforcement administration
duchenne
What
fda
5
×
second
5
×
drug
approval
medicine
approved
new
nod
oks
rna
therapeutics
won
acute
addresses
ago
alnylam
betting
billion
biopharma
cancer
causes
cholesterol
combo
condition
deal
decades
deeper
dna
duchenne
eli
esperion
esperion’s
fingerprint
friday
gene
genetic
giant
giving
going
historic
Language
unset
Current search:
second
×
fda
×
" national blog main "
×
@xconomy.com
4 years ago
Esperion’s Combo Pill for Lowering Cholesterol Levels Wins FDA Nod
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug